Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV - report from ACC2024

Professor Kathryn L. Berlacher shared his insights on Late-Breaking Clinical Trials IV, presented during at ACC.24: - Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycline-induced Cardiotoxicity (PROACT) - Topical Tranexamic Acid To Reduce Seizures In Cardiac Surgery - Efficacy And Safety Of Ninerafaxstat, A Novel Cardiac Mitotrope, In Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results Of IMPROVE-HCM - A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study Video: https://medicaldigest.org/scientific-contents/interview:joint-american-college-cardiologyjournal-american-medical-association-late-breaking-clinical-trials-iv